These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1305 related items for PubMed ID: 21555003

  • 1. Bisphosphonates: the first 40 years.
    Russell RG.
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [Abstract] [Full Text] [Related]

  • 2. Bisphosphonates: from bench to bedside.
    Russell RG.
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [Abstract] [Full Text] [Related]

  • 3. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

  • 4. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG.
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [Abstract] [Full Text] [Related]

  • 5. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH.
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [Abstract] [Full Text] [Related]

  • 6. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG, Rogers MJ.
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [Abstract] [Full Text] [Related]

  • 7. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA, Rodan GA.
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [Abstract] [Full Text] [Related]

  • 8. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S, Kamiya S, Ono K.
    Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
    [Abstract] [Full Text] [Related]

  • 9. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
    Ebetino FH, Sun S, Cherian P, Roshandel S, Neighbors JD, Hu E, Dunford JE, Sedghizadeh PP, McKenna CE, Srinivasan V, Boeckman RK, Russell RGG.
    Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
    [Abstract] [Full Text] [Related]

  • 10. Biochemical and molecular mechanisms of action of bisphosphonates.
    Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J.
    Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
    [Abstract] [Full Text] [Related]

  • 11. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V, Clézardin P.
    Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
    Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP.
    J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
    [Abstract] [Full Text] [Related]

  • 13. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
    Räikkönen J, Taskinen M, Dunford JE, Mönkkönen H, Auriola S, Mönkkönen J.
    Biochem Biophys Res Commun; 2011 Apr 22; 407(4):663-7. PubMed ID: 21420384
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 15. Physiology of the aging bone and mechanisms of action of bisphosphonates.
    Dominguez LJ, Di Bella G, Belvedere M, Barbagallo M.
    Biogerontology; 2011 Oct 01; 12(5):397-408. PubMed ID: 21695491
    [Abstract] [Full Text] [Related]

  • 16. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb 01; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 17. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
    Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH.
    Bone; 2006 May 01; 38(5):617-27. PubMed ID: 16046206
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B, Ling Chau JF, Wang X, Leong WF.
    J Cell Biochem; 2011 May 01; 112(5):1229-42. PubMed ID: 21465521
    [Abstract] [Full Text] [Related]

  • 19. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
    Russell RG, Watts NB, Ebetino FH, Rogers MJ.
    Osteoporos Int; 2008 Jun 15; 19(6):733-59. PubMed ID: 18214569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.